Other Events ·
iSpecimen Inc. received a Nasdaq Deficiency Letter on September 8, 2026, for failing to maintain minimum stockholders'…
ISPCiSpecimen Inc.
iSpecimen Inc. received a Nasdaq Deficiency Letter on September 8, 2026, for failing to maintain minimum stockholders' equity under Listing Rule 5550(b). Nasdaq granted an extension until November 25, 2026, to regain compliance. The company cites a private placement closing May 11, 2026, which generated approximately $2.5 million in gross proceeds, and plans for a best-efforts public offering of approximately $5 million. Financial projections indicate stockholders' equity of roughly $5.1 million through June 30, 2027. Failure to evidence compliance by the deadline or in the next periodic report may result in delisting from the Nasdaq Capital Market. iSpecimen Inc. operates in the healthcare technology industry, providing digital pathology solutions.